Nuvectis Pharma Q3 2026 earnings
Net loss widened to $30.1 million driven by a $20.0 million upfront license payment for NXP100 and NXP200, though cash position strengthened to $140.7 million.
Headline numbers
not stated in the 8-K
Revenue breakdown
not stated in the 8-K
Margins and costs
- Gross margin not stated in the 8-K
- Operating expenses $31.0 million (+299% YoY)
- One-offs in the quarter $20.0 million upfront payment for NXP100 and NXP200 license agreement; $1.8 million milestone associated with NXP900
- Effective tax rate not stated in the 8-K
- Non-GAAP bridge Net loss of $5.8 million excludes $20.0 million upfront license payment, $1.8 million milestone, and $2.4 million stock-based compensation.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Basic and diluted net loss per common share outstanding | -$1.02 | -$0.30 | -$0.44 | -$0.68 vs prior quarter |
| Weighted average number of common shares outstanding | 29.5 million | 23.5 million | 22.7 million | +25.6% vs prior quarter |
Guidance
not stated in the 8-K
What drove it
- Revenue story No revenue reported; company is in clinical development.
- EPS story Net loss per share widened due to increased operating expenses and a higher share count, driven by license payments and hiring.
- One-off check $20.0 million upfront payment for NXP100 and NXP200 license agreement; $1.8 million milestone associated with NXP900.
The good
- Cash position strengthened to $140.7 million, the strongest in company history
- Hired Dr. Dustin Little, M.D., as SVP Clinical Development and head of the Complement program
The bad
- Net loss widened to $30.1 million from $7.5 million in Q3 2025
- Research and development expenses surged to $27.4 million driven by license payments
The ugly
- none
Open questions
- What is the specific regulatory path forward for ciprocopan in PNH?
- When will the U.S. IND for NXP100 be submitted?
- When will the U.S. IND for NXP200 be submitted?
- When will additional NXP200 Phase 1b data from China be presented?
Full release
Nuvectis Pharma (NVCT) earnings release, November 4, 2026
Nuvectis
Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
FDA discussions ongoing regarding the U.S. regulatory path forward for ciprocopan in patients with PNH; An update is expected before year-end.
Nuvectis will hold a conference call today at 8:00 AM ET to discuss business highlights and its third quarter 2026 financial results.
November 4,
2026, Fort Lee, NJ - Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, announced today its financial results for the third quarter of 2026 and provided an update on recent business progress.
"The last few months have been truly transformational for Nuvectis," said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis.
"The strategic in-licensing of ciprocopan (NXP100, our CFBi) and NXP200 (our paradox-breaker BRAF inhibitor) firmly establishes
Nuvectis as a late-stage clinical development company with potential best-in-class assets. Our immediate priority is to advance ciprocopan toward a U.S. marketing application in PNH, as well as in additional indications. Our discussions with the FDA regarding the next steps for PNH are well underway, and we expect to provide an update before year-end. We plan to submit a U.S. IND for NXP100 by year-end. In parallel, we are building out our internal complement expertise to support a broad development program. Recently, we strengthened our team with the hiring of Dustin Little, M.D., a SVP Clinical Development and head of our Complement program. Dr. Little is a physician-scientist and board-certified nephrologist and brings the ideal combination of relevant industry experience, having worked in clinical development at AstraZeneca for a decade, and as a physician. We are excited to have him join the team."
Mr. Bentsur continued, "With its potential for a clear dosing convenience compared to injectable treatments and Fabhalta—the twice-daily oral CFBi—and supported by robust clinical data in PNH and IgAN as well as validating clinical data from the Fabhalta clinical trials, we believe ciprocopan has the potential to redefine the standard of care for patients in targeted settings.”
“For
NXP200, updated Phase 1b results in BRAF V600-mutated recurrent or progressive glioma were presented at the recent ESMO annual meeting.
Single-agent NXP200 demonstrated durable responses, including complete responses, with activity also seen in patients previously treated with a BRAF inhibitor. The data are encouraging and underscore the potential of NXP200 to become a differentiated, best-in-class, second-generation, paradox-breaker BRAF inhibitor. We expect to submit a U.S. IND for NXP200 by year-end, and we look forward to providing additional NXP200
Phase 1b data from China, alongside a Phase 1b data update for NXP900, our SRC-Yes1 kinase inhibitor,in the coming months."
"We ended the quarter with approximately $140 million in cash, representing the strongest financial position in Nuvectis’ history,"
Mr. Bentsur concluded. "We expect this funding to support our operations into the second half of 2029, providing a runway that extends well beyond multiple potential value-creating clinical and regulatory milestones."
Recent
Developments
Ciprocopan
(NXP100)
NXP200
NXP900
Corporate
Updates: Recent Hire Strenthens Our Clinical Development Team
Dustin
Little, MD, joined Nuvectis as Senior Vice President, Head of the Complement program, in September 2026. Dr. Little is a physician-scientist and board-certified nephrologist with a decade of pharmaceutical industry experience driving drug development from asset acquisition through program design, regulatory submission and approval. From 2016-2026, Dr. Little worked at Astra Zeneca and most recently served as Global Clinical Head, Late Cardiovascular, Renal, and Metabolism (CVRM), providing clinical leadership for renal disease area strategy at AstraZeneca as well as multiple first-in-class/potential first-in-class treatments for people living with kidney, cardiovascular, or hematologic diseases. Dr. Little also represented AstraZeneca externally in regulatory interactions and on major industry, academic and drug development advisory bodies.
Dr. Little earned his doctorate degree from the University of Washington School of Medicine in 2007. Between 2007-2016 Dr. Little served in the US military during which time he completed his internal medicine residency at the Madigan Army Medical Center and nephrology fellowship at the Walter Reed National Medical Center. In 2013, Dr. Little deployed to Afghanistan as a squadron physician. Dr. Little continues to treat patients as a volunteer at a Washington, DC-area nephrology clinic.
Mr. Bentsur said, “We welcome Dustin to Nuvectis. Dustin has had an immediate impact on the NXP100 program including involvement in the FDA discussions for PNH, conducting prioritization assessments of other indications, protocol writing and interactions with top key opinion leaders. Dustin’s knowledge and understanding of the complement inhibition in nephrology and hematology diseases are exceptional and we look forward to harnessing his expertise as we set out to establish NXP100 as a potential best-in-class compound across several indications.”
Dr. Little commented, “It’s exciting to join Nuvectis at such a transformative time. The company has built a strong foundation and NXP100, as a late-stage once-a-day oral CFBi, represents a unique opportunity for significant impact across several indications. Leveraging my industry experience and medical knowledge, I look forward to helping spearhead this program forward while utilizing the compelling... (truncated)er CFBi data as a roadmap for our development plans.”
Third
Quarter 2026 Financial Results
Cash and cash equivalents were $140.7 million as of September 30, 2026, compared to $31.6 million as of December 31, 2025. In July, the Company raised $115.0 million in gross proceeds in a follow-on offering and additional $39.5 million of cash was raised via the existing
ATM of which $37.0 million placed with a single healthcare dedicated fund.
The
Company's net loss was $30.1 million for the three months ended September 30, 2026, compared to $7.5 million for the three months ended September 30, 2025, an increase in net loss of $22.6 million, which includes a one-time upfront payment associated with the
NXP100 and NXP200 license agreement of $20.0 million, and $1.8 million in milestones associated with NXP900. Non-cash stock-based compensation was $2.4 million for the three months ended September 30, 2026, compared to $1.5 million for the three months ended September 30,
2025. Net of the up-front license payment, the one-time milestone associated with NXP900 and non-cash stock-based compensation, the net loss for the third quarter 2026 was $5.8 million.
Research and development expenses were $27.4 million for the three months ended September 30, 2026, compared to $5.8 million for the three months ended September 30, 2025, an increase of $21.6 million. The increase was primarily driven by the $20.0 million upfront payment for the NXP100 and NXP200 license agreement, $1.8 million in milestones associated with NXP900, a $1.2 million increase in employee compensation and benefits, $0.5 million increase in clinical trial expenses and a $0.1 million increase in manufacturing costs, partially offset by
$2.0 million in license fees paid in 2025. Non-cash stock-based compensation was $1.5 million for the three months ended September 30,
2026, compared to $0.9 million for the three months ended September 30, 2025.
General and administrative expenses were $3.7 million for the three months ended September 30, 2026, compared to $2.0 million for the three months ended September 30, 2025, an increase of $1.7 million. The increase was primarily driven by a $1.2 million increase in professional and consulting services and a $0.4 million increase in employee compensation and benefits. Non-cash stock-based compensation was $0.9 million for the three months ended September 30, 2026, compared to $0.6 million for the three months ended September 30, 2025.
Finance income was $1.0 million for the three months ended September 30, 2026, and $0.3 million for the three months ended September 30,
2025.
Conference
Call and Webcast Information:
Time:
8:00 AM ET
Date:
Wednesday, November 4, 2026
Participant
Dial-In (U.S.): 1-877-407-0752
Participant
Dial-In (International): 1-201-389-0912
Conference
ID: 13763643
Webcast
Access: Please click here
The live and archived webcast can also be accessed by visiting the Nuvectis Pharma website on the Events and Presentations section of the
Investor Relations page. A replay of the webcast will be archived for at least 30 days following the presentation.
About
Nuvectis Pharma, Inc.
Nuvectis
Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company’s pipeline includes ciprocopan (NXP100), a complement Factor
B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP900 and NXP200, in development for the treatment of advanced cancers.
The company’s lead drug candidate is ciprocopan, a once-a-day Factor B inhibitor, with best-in-class potential, recently approved in
China for the treatment of PNH patients previously untreated with complement inhibitors.
NXP200 is an oral, brain-penetrant, paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II/III non-V600-mutated solid tumor malignancies, with best-in-class potential.
NXP900 is an oral small molecule inhibitor of the SRC family kinases, including SRC and YES1.
Forward
Looking Statements
Financial statements
Income Statement
Three Months Ended September 30 — (USD in thousands, except per share and share amounts)
| Three Months Ended September 30 – 2026 | Three Months Ended September 30 – 2025 | Nine Months Ended September 30 – 2026 | Nine Months Ended September 30 – 2025 | |
|---|---|---|---|---|
| OPERATING EXPENSES | ||||
| Research and development | 27,370 | 5,774 | 36,160 | 13,067 |
| General and administrative | 3,679 | 2,020 | 8,346 | 6,890 |
| OPERATING LOSS | -31,049 | -7,794 | -44,506 | -19,957 |
| Finance income | 979 | 332 | 1,366 | 829 |
| NET LOSS | -30,070 | -7,462 | -43,140 | -19,128 |
| NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | -30,070 | -7,462 | -43,140 | -19,128 |
| EFFECT OF WARRANTS MODIFICATION, | -2,429 | -2,429 | ||
| TOTAL NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | -30,070 | -9,891 | -43,140 | -21,557 |
| BASIC AND DILUTED NET LOSS PER COMMON SHARE OUTSTANDING | -1.02 | -0.44 | -1.69 | -1.01 |
| Basic and diluted weighted average number of common shares outstanding | 29,466,698 | 22,719,057 | 25,474,553 | 21,351,228 |
Balance Sheet
September 30, — (USD in thousands, except per share and share amounts)
| September 30, – 2026 | December 31, – 2025 | |
|---|---|---|
| CURRENT ASSETS | ||
| Cash and cash equivalents | 140,707 | 31,634 |
| Other current assets | 132 | 75 |
| TOTAL CURRENT ASSETS | 140,839 | 31,709 |
| TOTAL ASSETS | 140,839 | 31,709 |
| CURRENT LIABILITIES | ||
| Accounts payable | 5,761 | 6,274 |
| Accrued liabilities | 2,109 | 115 |
| Employee compensation and benefits | 6,323 | 6,907 |
| TOTAL CURRENT LIABILITIES | 14,193 | 13,296 |
| TOTAL LIABILITIES | 14,193 | 13,296 |
| SHAREHOLDERS’ EQUITY, | ||
| Additional paid in capital | 269,473 | 118,100 |
| Accumulated deficit | -142,827 | -99,687 |
| TOTAL SHAREHOLDERS’ EQUITY | 126,646 | 18,413 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | 140,839 | 31,709 |
Cash Flow
From the 10-Q · Nine Months Ended September 30, — (unaudited) (in thousands)
| Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | -43,140 | -19,128 |
| Adjustments to reconcile loss to net cash used in operating activities: Cost of share-based payments | 5,980 | 4,556 |
| Changes in operating assets and liabilities: | ||
| Increase in other current assets | -57 | -71 |
| (Decrease)/increase in accounts payable | -513 | 3,941 |
| Increase/(decrease) in accrued liabilities | 1,994 | -775 |
| Decrease in employee compensation and benefits | -584 | -558 |
| Net cash used in operating activities | -36,320 | -12,035 |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Proceeds from issuance of common shares - At-the market offering | 39,667 | 15,437 |
| Issuance costs related to At-the-market offering | -1,189 | -466 |
| Proceeds from exercise of warrants | 138 | |
| Proceeds from public offering | 115,000 | 15,525 |
| Issuance costs related to public offering | -8,223 | -1,552 |
| Net cash provided by financing activities | 145,393 | 28,944 |
| INCREASE IN CASH AND CASH EQUIVALENTS | 109,073 | 16,909 |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 31,634 | 18,533 |
| CASH AND CASH EQUIVALENTS AT END OF PERIOD | 140,707 | 35,442 |
| Supplemental noncash disclosure of investing and financing activities: | ||
| Unpaid issuance costs related to ATM | 75 | |
This press release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as
"anticipate", "believe", "contemplate", "could", "estimate", "expect", "intend",
"seek", "may", "might", "plan", "potential", "predict", "project",
"target", "aim", "should", "will", "would", or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the use of proceeds from the public offering and the approvability and market potential of our pipeline products. Forward looking statements are based on Nuvectis’ current expectations, estimates and projections and past interpretations of data and information available, including preclinical and clinical safety, pharmacokinetics, pharmacodynamics, and efficacy data generated to date for its pipeline products NXP100, NXP200, and NXP900, estimates and projections regarding Nuvectis’ financial condition and IND submissions and future clinical trials for NXP100 and NXP200. The outcomes of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other conditions, and other factors that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events... (truncated)nd uncertainties may also be subject to market and other conditions and described more fully in the section titled "Risk Factors" in Nuvectis’ third quarter 2026 Form 10-Q and Nuvectis’ other public filings with the U.S. Securities and Exchange Commission ("SEC"). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Nuvectis’ expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Company
Contact
Ron
Bentsur
Chairman,
Chief Executive Officer and President rbentsur@nuvectis.com
Media
Relations Contact
Kevin
Gardner
LifeSci
Advisors kgardner@lifesciadvisors.com
NUVECTIS
PHARMA, INC.
BALANCE
SHEET
(USD in thousands, except per share and share amounts)
* Represents an amount lower than $1,000 USD.
NUVECTIS
PHARMA, INC.
STATEMENT
OF OPERATIONS
(USD in thousands, except per share and share amounts)